LDB2

Summary

LDB2 (LIM domain binding 2, HGNC:6533) is a protein-coding gene on chromosome 4p15.32, encoding LIM domain-binding protein 2 (O43679). Transcription cofactor. It is a selective cancer dependency (DepMap: 14.7% of cell lines).

The protein encoded by this gene belongs to the LIM-domain binding family. Members of this family are characterized by a conserved nuclear localization sequence, an amino-terminal homodimerization domain and a carboxy-terminal LIM interaction domain. These proteins function as adapter molecules to allow assembly of transcriptional regulatory complexes. Genetic association studies suggest functions for this gene in rhegmatogenous retinal detachment and coronary artery disease. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 9079 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 40 total
• Cancer dependency (DepMap): dependent in 14.7% of screened cell lines
• MANE Select transcript: NM_001290

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6533
Approved symbol	LDB2
Name	LIM domain binding 2
Location	4p15.32
Locus type	gene with protein product
Status	Approved
Aliases	CLIM1, LDB1
Ensembl gene	ENSG00000169744
Ensembl biotype	protein_coding
OMIM	603450
Entrez	9079

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 10 protein_coding, 6 protein_coding_CDS_not_defined, 2 retained_intron, 2 nonsense_mediated_decay

ENST00000304523, ENST00000441778, ENST00000502640, ENST00000503153, ENST00000503829, ENST00000504189, ENST00000504886, ENST00000506732, ENST00000507464, ENST00000508804, ENST00000508918, ENST00000509803, ENST00000510825, ENST00000512345, ENST00000513457, ENST00000515064, ENST00000854229, ENST00000854230, ENST00000854231, ENST00000854232

RefSeq mRNA: 4 — MANE Select: NM_001290 NM_001130834, NM_001290, NM_001304434, NM_001304435

CCDS: CCDS3420, CCDS47031, CCDS77902, CCDS77903

Canonical transcript exons

ENST00000304523 — 8 exons

Exon	Start	End
ENSE00002064728	16898354	16898645
ENSE00003511794	16759158	16759260
ENSE00003568401	16508535	16508686
ENSE00003577402	16585922	16586005
ENSE00003594803	16511981	16512104
ENSE00003627305	16595703	16595875
ENSE00003637535	16588710	16588832
ENSE00003668908	16501541	16502873

Expression profiles

Bgee: expression breadth ubiquitous, 270 present calls, max score 98.56.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 25.1095 / max 596.7868, expressed in 1035 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
51518	18.9621	978
51516	1.5776	582
51520	0.9354	524
51515	0.7666	383
51517	0.7487	379
51521	0.7426	457
51514	0.6484	269
51519	0.3585	216
51522	0.3214	138
51505	0.0482	23

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lung	UBERON:0002167	98.56	gold quality
cortical plate	UBERON:0005343	97.91	gold quality
Brodmann (1909) area 23	UBERON:0013554	97.82	gold quality
middle temporal gyrus	UBERON:0002771	97.14	gold quality
body of uterus	UBERON:0009853	96.77	gold quality
superior frontal gyrus	UBERON:0002661	96.71	gold quality
vena cava	UBERON:0004087	96.52	gold quality
Brodmann (1909) area 10	UBERON:0013541	96.39	gold quality
primary visual cortex	UBERON:0002436	96.13	gold quality
frontal pole	UBERON:0002795	96.00	gold quality
omental fat pad	UBERON:0010414	95.68	gold quality
adipose tissue of abdominal region	UBERON:0007808	95.67	gold quality
peritoneum	UBERON:0002358	95.66	gold quality
calcaneal tendon	UBERON:0003701	95.62	gold quality
prefrontal cortex	UBERON:0000451	95.58	gold quality
upper lobe of left lung	UBERON:0008952	95.53	gold quality
pericardium	UBERON:0002407	95.47	gold quality
occipital lobe	UBERON:0002021	95.44	gold quality
stromal cell of endometrium	CL:0002255	95.43	gold quality
endocervix	UBERON:0000458	95.42	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.41	gold quality
upper lobe of lung	UBERON:0008948	95.39	gold quality
postcentral gyrus	UBERON:0002581	95.32	gold quality
lung	UBERON:0002048	95.17	gold quality
adipose tissue	UBERON:0001013	95.12	gold quality
parietal lobe	UBERON:0001872	95.09	gold quality
subcutaneous adipose tissue	UBERON:0002190	94.97	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.85	gold quality
Brodmann (1909) area 46	UBERON:0006483	94.71	gold quality
orbitofrontal cortex	UBERON:0004167	94.67	gold quality

Single-cell (SCXA)

Detected in 25 experiment(s), a significant marker in 23.

Experiment	Marker?	Max mean expression
E-ANND-2	yes	6940.63
E-GEOD-131882	yes	6484.08
E-CURD-119	yes	5060.89
E-MTAB-11268	yes	4798.60
E-HCAD-35	yes	1296.30
E-HCAD-25	yes	951.44
E-CURD-112	yes	745.42
E-GEOD-109979	yes	163.23
E-CURD-53	yes	114.24
E-MTAB-10287	yes	75.93
E-HCAD-10	yes	58.48
E-MTAB-10553	yes	54.57
E-HCAD-1	yes	47.24
E-GEOD-134144	yes	43.97
E-GEOD-135922	yes	37.13

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

67 targeting LDB2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-8062	99.88	68.43	995
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-545-5P	99.66	70.18	2308

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 14.7% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 6)

• The transcription co-factor LIM domain binding 2 (LDB2) was identified as a potential high-hierarchy regulator of the atherosclerosis-module. (PMID:19997623)
• LDB2 was the most connected gene in a transcription factor regulatory network inferred from transendothelial migration of leukocyte and atherosclerosis module genes in coronary and carotid artery disease macrophages. (PMID:24925974)
• The regulation of DLL4 by the LDB2 complex provides a novel mechanism of DLL4 transcriptional control that may be exploited to develop therapeutics for aberrant vascular remodeling. (PMID:28946938)
• Cooperation of LIM domain-binding 2 (LDB2) with EGR in the pathogenesis of schizophrenia. (PMID:33656268)
• [LIM-domain binding protein 2 regulated by m(6)A modification inhibits lung adenocarcinoma cell proliferation in vitro]. (PMID:33849822)
• LIM-domain binding protein 2 was down-regulated by miRNA-96-5p inhibited the proliferation, invasion and metastasis of lung cancer H1299 cells. (PMID:36473369)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	ldb2a	ENSDARG00000019579
danio_rerio	ldb2b	ENSDARG00000034896
mus_musculus	Ldb2	ENSMUSG00000039706
rattus_norvegicus	Ldb2	ENSRNOG00000003205
drosophila_melanogaster	Chi	FBGN0013764
caenorhabditis_elegans		WBGENE00002261

Paralogs (1): LDB1 (ENSG00000198728)

Protein

Protein identifiers

LIM domain-binding protein 2 — O43679 (reviewed: O43679)

Alternative names: Carboxyl-terminal LIM domain-binding protein 1, LIM domain-binding factor CLIM1

All UniProt accessions (7): D6RAT1, E7EX95, E9PFI4, E9PGU0, O43679, G5E9Y7, H0YA09

UniProt curated annotations — full annotation on UniProt →

Function. Transcription cofactor. Binds to the LIM domain of a wide variety of LIM domain-containing transcription factors.

Subunit / interactions. Interacts with LHX9. Interacts with SLK; leading to negatively regulate SLK kinase activity. Interacts with LMO4.

Subcellular location. Nucleus.

Post-translational modifications. Ubiquitinated by RLIM/RNF12, leading to its degradation by the proteasome.

Miscellaneous. Lacks LIM-binding domain.

Similarity. Belongs to the LDB family.

Isoforms (3)

UniProt ID	Names	Canonical?
O43679-1	1, a, CLIM1a	yes
O43679-2	2, b, CLIM1b
O43679-3	3

RefSeq proteins (4): NP_001124306, NP_001281, NP_001291363, NP_001291364 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029005	LIM-bd/SEUSS	Family
IPR041363	LID	Domain

Pfam: PF01803, PF17916

UniProt features (10 total): splice variant 4, region of interest 2, compositionally biased region 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43679-F1	73.80	0.43

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 539 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_HEMOGLOBIN_METABOLIC_PROCESS, GOBP_CHROMOSOME_ORGANIZATION, GOBP_HINDBRAIN_DEVELOPMENT, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_SOMATIC_STEM_CELL_POPULATION_MAINTENANCE, GOBP_METENCEPHALON_DEVELOPMENT, GOBP_AXIS_SPECIFICATION, GOBP_MYELOID_CELL_HOMEOSTASIS, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, CCAWYNNGAAR_UNKNOWN, GOBP_REGULATION_OF_PHOSPHORYLATION, RORA1_01, GCANCTGNY_MYOD_Q6, GOBP_FOCAL_ADHESION_ASSEMBLY

GO Biological Process (9): negative regulation of transcription by RNA polymerase II (GO:0000122), hair follicle development (GO:0001942), nervous system development (GO:0007399), epithelial structure maintenance (GO:0010669), regulation of cell migration (GO:0030334), somatic stem cell population maintenance (GO:0035019), regulation of kinase activity (GO:0043549), positive regulation of cellular component biogenesis (GO:0044089), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (4): transcription coregulator activity (GO:0003712), enzyme binding (GO:0019899), LIM domain binding (GO:0030274), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), nucleoplasm (GO:0005654), transcription regulator complex (GO:0005667), nucleolus (GO:0005730), plasma membrane (GO:0005886), cell leading edge (GO:0031252)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
nuclear lumen	2
cellular anatomical structure	2
negative regulation of DNA-templated transcription	1
hair cycle process	1
anatomical structure development	1
skin epidermis development	1
system development	1
tissue homeostasis	1
cell migration	1
regulation of cell motility	1
stem cell population maintenance	1
kinase activity	1
regulation of phosphorylation	1
regulation of transferase activity	1
cellular component biogenesis	1
regulation of cellular component biogenesis	1
positive regulation of cellular process	1
positive regulation of DNA-templated transcription	1
transcription regulator activity	1
protein binding	1
protein domain specific binding	1
binding	1
intracellular membrane-bounded organelle	1
protein-containing complex	1
intracellular membraneless organelle	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1576 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LDB2	LMO2	P25791	998
LDB2	TAL1	P17542	995
LDB2	GATA1	P15976	995
LDB2	TCF3	P15883	992
LDB2	GATA2	P23769	982
LDB2	CBFA2T3	O75081	981
LDB2	LYL1	P12980	965
LDB2	ISL1	P20663	944
LDB2	LMO1	P25800	922
LDB2	LHX2	P50458	907
LDB2	LHX3	Q9UBR4	907
LDB2	ZFPM1	Q8IX07	900
LDB2	RUNX1	Q01196	882
LDB2	BEX2	Q9BXY8	875
LDB2	BEX1	Q9HBH7	875

IntAct

93 interactions, top by confidence:

A	B	Type	Score
LDB2	LMO4	psi-mi:“MI:0915”(physical association)	0.800
LMO4	LDB2	psi-mi:“MI:0915”(physical association)	0.800
LDB2	TSNAX	psi-mi:“MI:0915”(physical association)	0.670
MYDGF	LDB2	psi-mi:“MI:0915”(physical association)	0.560
LDB2	MYDGF	psi-mi:“MI:0915”(physical association)	0.560
LDB2	LNX1	psi-mi:“MI:0915”(physical association)	0.560
LDB2	LHX8	psi-mi:“MI:0915”(physical association)	0.560
LDB2	LMO3	psi-mi:“MI:0915”(physical association)	0.560
LDB2	GGACT	psi-mi:“MI:0915”(physical association)	0.560
LDB2	DGCR6L	psi-mi:“MI:0915”(physical association)	0.560
LDB2	TTC19	psi-mi:“MI:0915”(physical association)	0.560
LDB2	NTAQ1	psi-mi:“MI:0915”(physical association)	0.560
LDB2	LMO1	psi-mi:“MI:0915”(physical association)	0.560
LDB2	PSMB1	psi-mi:“MI:0915”(physical association)	0.560
SDCBP	LDB2	psi-mi:“MI:0915”(physical association)	0.560
LDB2	C14orf119	psi-mi:“MI:0915”(physical association)	0.560
LDB2	EGLN3	psi-mi:“MI:0915”(physical association)	0.560
LDB2	HDAC7	psi-mi:“MI:0915”(physical association)	0.560
LDB2	EPM2AIP1	psi-mi:“MI:0915”(physical association)	0.560
LDB2	EXOC3L1	psi-mi:“MI:0915”(physical association)	0.560
CETN3	LDB2	psi-mi:“MI:0915”(physical association)	0.560
LDB2	SMARCD1	psi-mi:“MI:0915”(physical association)	0.560
LDB2	LMO2	psi-mi:“MI:0915”(physical association)	0.560
LDB2	LMO3	psi-mi:“MI:0915”(physical association)	0.550
LDB2	SSBP3	psi-mi:“MI:0915”(physical association)	0.550

BioGRID (37): LHX4 (Two-hybrid), LMO3 (Two-hybrid), LMO4 (Two-hybrid), RASIP1 (Two-hybrid), RILP (Two-hybrid), SSBP2 (Two-hybrid), SSBP3 (Two-hybrid), TSNAX (Two-hybrid), LDB2 (Affinity Capture-MS), LDB2 (Two-hybrid), LDB2 (Two-hybrid), LDB2 (Two-hybrid), LDB2 (Two-hybrid), LDB2 (Two-hybrid), LDB2 (Two-hybrid)

ESM2 similar proteins: A1C602, A1DG01, A1DMG9, A2QFG8, A2VDM8, A5DF43, A6SP81, A7EAG1, B0XVV1, B1AWL2, B6HSQ3, B6Q3B6, B8LT44, B8N6M6, C4JFE4, C4R1K8, C5FP02, C5PHH6, C7YM38, D4AL61, D4D2Y6, E4UP58, E5DG73, O42252, O43679, O55203, P28348, P28349, P52959, P70060, Q03297, Q05534, Q0CHR0, Q13233, Q1EQW7, Q2UD93, Q2UMM2, Q2YDF2, Q4WHB7, Q4WHD1

Diamond homologs: G5EEL0, O42252, O43679, O55203, O73715, P70060, P70662, Q1EQW7, Q6NVL6, Q86U70, Q9W676

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
RLIM	“down-regulates quantity by destabilization”	LDB2	polyubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

40 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

4405 predictions. Top by Δscore:

Variant	Effect	Δscore
4:16508533:A:AC	donor_gain	1.0000
4:16508534:C:CC	donor_gain	1.0000
4:16508682:TTCTG:T	acceptor_gain	1.0000
4:16508683:TCTG:T	acceptor_loss	1.0000
4:16508684:CTG:C	acceptor_gain	1.0000
4:16508685:TG:T	acceptor_gain	1.0000
4:16508686:GC:G	acceptor_loss	1.0000
4:16508687:C:CC	acceptor_gain	1.0000
4:16508687:C:CG	acceptor_loss	1.0000
4:16508688:T:A	acceptor_loss	1.0000
4:16508691:A:T	acceptor_gain	1.0000
4:16508692:A:AC	acceptor_gain	1.0000
4:16508694:A:C	acceptor_gain	1.0000
4:16512100:CACAA:C	acceptor_gain	1.0000
4:16512102:CAA:C	acceptor_gain	1.0000
4:16512105:C:CC	acceptor_gain	1.0000
4:16585920:AC:A	donor_gain	1.0000
4:16585921:CC:C	donor_gain	1.0000
4:16588704:A:AC	donor_gain	1.0000
4:16588705:C:CC	donor_gain	1.0000
4:16588706:TTA:T	donor_loss	1.0000
4:16588707:TAC:T	donor_loss	1.0000
4:16588708:A:AC	donor_gain	1.0000
4:16588708:A:AT	donor_loss	1.0000
4:16588708:ACATG:A	donor_gain	1.0000
4:16588709:C:CG	donor_gain	1.0000
4:16588709:CA:C	donor_gain	1.0000
4:16588709:CAT:C	donor_gain	1.0000
4:16588709:CATG:C	donor_gain	1.0000
4:16588709:CATGC:C	donor_gain	1.0000

AlphaMissense

2487 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:16502790:G:C	N325K	1.000
4:16502790:G:T	N325K	1.000
4:16502797:A:G	L323S	1.000
4:16502799:T:A	R322S	1.000
4:16502799:T:G	R322S	1.000
4:16502800:C:G	R322T	1.000
4:16502806:A:C	I320S	1.000
4:16502806:A:G	I320T	1.000
4:16502806:A:T	I320N	1.000
4:16502811:C:A	R318S	1.000
4:16502811:C:G	R318S	1.000
4:16502812:C:A	R318M	1.000
4:16502851:G:T	P305Q	1.000
4:16502852:G:A	P305S	1.000
4:16502852:G:T	P305T	1.000
4:16512003:C:A	W239C	1.000
4:16512003:C:G	W239C	1.000
4:16512005:A:G	W239R	1.000
4:16512005:A:T	W239R	1.000
4:16512012:A:C	F236L	1.000
4:16512012:A:T	F236L	1.000
4:16512013:A:C	F236C	1.000
4:16512013:A:G	F236S	1.000
4:16512014:A:G	F236L	1.000
4:16512016:A:C	L235W	1.000
4:16512028:A:G	L231P	1.000
4:16512028:A:T	L231Q	1.000
4:16512030:G:C	C230W	1.000
4:16512031:C:T	C230Y	1.000
4:16512032:A:G	C230R	1.000

dbSNP variants (sampled 300 via entrez): RS1000005978 (4:16775610 A>G), RS1000025497 (4:16622522 A>G), RS1000031377 (4:16883963 T>A,C), RS1000031502 (4:16858330 A>G), RS1000032669 (4:16581158 T>G), RS1000052430 (4:16760431 G>T), RS1000055580 (4:16571499 A>G), RS1000056785 (4:16851351 C>G,T), RS1000074383 (4:16662870 T>C), RS10000826 (4:16887027 C>A,T), RS1000084451 (4:16686988 T>G), RS1000096559 (4:16647149 A>G), RS1000097965 (4:16885404 G>A), RS1000106674 (4:16858579 C>T), RS1000107207 (4:16817283 C>T)

Disease associations

OMIM: gene MIM:603450 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST001922_7	QT interval	7.000000e-06
GCST001966_4	Rhegmatogenous retinal detachment	5.000000e-06
GCST004025_22	Systemic juvenile idiopathic arthritis	4.000000e-06
GCST004790_1	Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer	9.000000e-08
GCST007326_2	Number of sexual partners	1.000000e-08
GCST008151_45	Waist circumference	5.000000e-06
GCST008160_40	Waist circumference	5.000000e-06
GCST010678_2	Liver fibrosis (total hepatic collagen content)	2.000000e-06
GCST011998_16	Glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia	1.000000e-05

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004682	QT interval
EFO:0008204	left ventricular diastolic function measurement
EFO:0008347	response to trastuzumab
EFO:0010576	liver fibrosis measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, decreases expression, affects cotreatment	6
bisphenol A	affects cotreatment, increases methylation, increases expression	3
trichostatin A	affects cotreatment, increases expression	3
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	3
Vorinostat	increases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Aflatoxin B1	affects expression, decreases methylation	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
methylmercuric chloride	decreases expression	1
methyleugenol	decreases expression	1
aflatoxin B2	increases methylation	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
theaflavin-3,3’-digallate	affects expression	1
Zoledronic Acid	increases expression	1
Arsenic Trioxide	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	decreases expression	1
Cadmium	decreases expression, increases abundance	1
Cocaine	decreases expression	1
Dexamethasone	increases expression, affects cotreatment	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Nickel	decreases expression	1
Phthalic Acids	increases methylation	1
Triclosan	increases expression	1
Vanadates	increases expression	1
Vitamin E	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.